唾液微生物组与血清代谢组学可补充临床生物标志物预测多中心肝硬化门诊队列的6个月住院
研究纳入10个中心565例病因已控制或根除的肝硬化门诊患者,基线采集临床资料、唾液和血清进行微生物组与代谢组分析,163例(29%)在6个月内住院,其中75%为肝相关住院。随机森林模型联合临床、微生物和代谢变量预测6个月住院的曲线下面积高于各单独变量,潜因子分析显示临床变量(MELD 3.0、血红蛋白、白蛋白)影响最大,其次为唾液微生物群,再次为血清代谢组。
要点
- 565例肝硬化门诊患者中163例(29%)发生6个月住院,75%为肝相关住院。
- 住院者基线唾液微生物α多样性较低(1.96±0.48 vs 2.09±0.45,p=0.018)。
- 联合临床、微生物和代谢变量的随机森林模型预测6个月住院的AUC高于各单独变量。
核心结论
- 在病因已控制的多中心北美肝硬化门诊队列中,血清代谢组学和唾液微生物组可补充临床变量以预测6个月住院。
研究设计与样本
- NACSELD3研究纳入来自10个中心的病因已控制或根除的肝硬化门诊患者,系统随访,基线记录临床/人口学及肝硬化资料并采集唾液和血清分别进行微生物组和代谢组分析。
- 共纳入565例患者(60.2岁,68%男性,35%酒精相关,33%代谢功能障碍相关脂肪性肝炎,21%为已根除HCV,MELD 3.0为12)。
主要发现
- 163例(29%)需要6个月住院,其中大多数(75%)为肝相关住院。
- 住院者肝硬化严重程度和合并症指数更差,但人口学特征和口腔健康变量相似。
- 住院者基线唾液微生物α多样性较低(1.96±0.48 vs 2.09±0.45,p=0.018),致病菌(链球菌属、密螺旋体属、肠球菌科)更多,共生菌(韦荣球菌属、普雷沃菌属、嗜血杆菌属、毛螺菌科spp)更少。
- 血清代谢组学监督分析显示住院与非住院患者基线显著分离,以微生物来源代谢物(苯乳酸、次级胆汁酸、吲哚类)、胆碱部分及多胺/GABA(3-脲基丙酸/亚精胺)代谢物最为突出。
- 随机森林模型使用临床、微生物和代谢变量的曲线下面积高于各单独变量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Prognosticating outcomes such as hospitalizations in outpatients with cirrhosis is challenging, especially with changing etiologies and demographics. This study aims to determine the impact of multi-omic strategies on outcome prediction. APPROACH AND RESULTS: NACSELD3 enrolls outpatients with cirrhosis with controlled/eradicated etiologies from 10 centers and follows them systematically. At baseline, clinical/demographic and cirrhosis details were recorded and saliva and serum samples were collected for microbiome and metabolome analysis, respectively. Multi-omic bioinformatic studies to determine the interaction of microbiota and metabolites with the clinical prediction of 6-month hospitalizations were performed. Five hundred sixty-five patients (60.2 y, 68% men, 35% alcohol, 33% metabolic dysfunction-associated steatohepatitis, 21%, eradicated HCV with MELD 3.0 12) were enrolled. One hundred sixty-three (29%) required 6-month hospitalizations; most (75%) were liver-related. Those hospitalized had worse cirrhosis severity and comorbidity indices but similar demographics and oral health variables. Salivary microbiome alpha-diversity was lower (1.96±0.48 vs. 2.09±0.45, p =0.018) with greater pathobionts ( Streptococcus , Treponema, Enterococcaceae) and lower commensal genhospitalized/noera ( Veillonella, Prevotella, Haemophilus , Lachnospiraceae spp) at baseline. Serum metabolomics showed significant separation at baseline between hospitalized/non-hospitalized patients using supervised analyses with microbial-origin (phenyllactate, secondary bile acids, indoles), choline moieties, and polyamine/GABA (3-ureidopropionate/spermidine) metabolites being most prominent. Area under the curve using random forest for clinical, microbial, and metabolomic variables was higher than that of these individually. Latent factor analysis showed clinical variables (MELD 3.0, hemoglobin, and albumin) with the greatest impact, followed by salivary microbiota and then serum microbiome for hospitalization prediction. CONCLUSIONS: In a multicenter North American outpatient cirrhosis cohort with controlled etiologies, serum metabolomics and salivary microbiome add to clinical variables to prognosticate 6-month hospitalization.
引用
- Bajaj JS, Reddy KR, Tandon P, et al. Salivary microbiome and serum metabolomics add to clinical biomarkers to predict 6-month hospitalizations in a multicenter cirrhosis outpatient cohort. Hepatology. 2025. PMID: 40632657. doi:10.1097/HEP.0000000000001462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。